Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06220669 · ClinicalTrials.gov registry record · Phase 2

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

A Phase 2 study of Multiple Sclerosis, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
20
Study locations

NCT06220669 is a Phase 2 study of Multiple Sclerosis that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 200 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06220669, a Phase 2 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.

Conditions Studied

Multiple Sclerosis

Interventions

  • DRUG Placebo
  • DRUG LY3541860

Study Locations (20)

Florida

  • Healthcare Innovations Institute, LLC - Coral Springs
  • Royal Palm Medical Group - Fort Myers
  • Eastern Medical Group Research - Fort Myers
  • Panhandle Research and Medical Clinic - Gulf Breeze
  • High Quality Research - Miami
  • USF MS Center - Tampa
  • Conquest Research LLC - Winter Park - ClinEdge - PPDS - Winter Park

Other

  • Centre Hospitalier Universitaire de Clermont Ferrand - Clermont-Ferrand
  • CHRU de Nancy - Nancy
  • CHU Gui De Chauliac - Nîmes
  • Centre Hospitalier Intercommunal - Site de Poissy - Poissy

Texas

  • ANRC Research - El Paso
  • Prolato Clinical Research Center - Houston
  • 1960 Family Practice, PA - Houston

Missouri

  • Sharlin Health and Neurology - Ozark
  • Psych Care Consultants Research - St Louis

Illinois

  • Consultants in Neurology - Northbrook

South Carolina

  • Premier Neurology - Greer

Tennessee

  • Hope Neurology - Knoxville

Washington

  • Swedish Multiple Sclerosis Center - Seattle

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-03-19
Est. Completion 2028-08
Phase Phase 2

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06220669

The ClinicalTrials.gov registry entry for NCT06220669 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (66% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06220669 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Other, Texas.

Frequently Asked Questions

What is clinical trial NCT06220669 about?

NCT06220669 is a clinical study titled "A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis". The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.

What is the current status of trial NCT06220669?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-03-19. Estimated completion is 2028-08.

What conditions does trial NCT06220669 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT06220669?

The interventions under investigation include: Placebo (DRUG), LY3541860 (DRUG).

Who is sponsoring clinical trial NCT06220669?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06220669 being conducted?

This trial has 20 study locations across Florida, Illinois, Missouri, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.